Hummingbird Bioscience licenses antibodies to Immunome

Hummingbird Bioscience has granted Immunome (IMNM) an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target. Under the terms of the license agreement, Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for future development and commercial milestone payments, as well as royalties.